Solnatide

Drug Profile

Solnatide

Alternative Names: AP-301

Latest Information Update: 15 Dec 2016

Price : $50

At a glance

  • Originator APEPTICO Forschung und Entwicklung
  • Class Peptides
  • Mechanism of Action Inflammasome inhibitors; P38 mitogen-activated protein kinase inhibitors; Sodium channel agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Reperfusion injury; Acute lung injury; Pulmonary oedema; Pseudohypoaldosteronism
  • New Molecular Entity Yes
  • Available For Licensing Yes - Influenza virus infections

Highest Development Phases

  • Phase II Acute lung injury; Adult respiratory distress syndrome; Pulmonary oedema; Reperfusion injury
  • Preclinical Pseudohypoaldosteronism

Most Recent Events

  • 15 Dec 2016 Pharmacodynamics data from a preclinical trial in Pulmonary oedema released by Apeptico
  • 02 Dec 2016 Solnatide licensed to Apeptico in various European markets
  • 10 Feb 2016 Phase-II development is ongoing in Austria
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top